MedTrace Logo

The Effect of Arterial Carbon Dioxide Levels on Cerebral Blood Flow and Cerebral Autoregulation in the Steep Trendelenburg Position During Robot-assisted Prostatectomy, and Its Effect on Postoperative Cognition

NCT06865027 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-12-29

No results posted yet for this study

Summary

Patients scheduled for robot-assisted prostatectomy will be randomized to either high or low concentrations of carbon dioxide in the blood. This will be managed by applying different ventilation strategies during anesthesia.The levels will be distinctly different.

The investigators will assess whether different concentrations of carbon dioxide in blood results in different brain blood flow levels and different intracranial pressure during laparascopic surgery in the head-down tilted position. The investigators also will assess if different carbon dioxide level will manifest in different cognitive abilities in the two study groups, measured on day 1 post-surgery.

Conditions

  • Intracranial Pressure
  • Circulation System
  • Cerebral Perfusion Pressure
  • Cognitive Function

Interventions

OTHER

Ventilation strategy

The selected PaCO2 targets are: Normocapnia: PaCO2: 5.0-5.5 kPa Hypercapnia: PaCO2: 6.4-7.0 kPa The adjustments on the ventilator needed to achieve these targets will be administered by the anesthetic nurse and attending anesthesiologist and held within the following limitations: Tidal volume: 4 - 8ml ml/kg IBW Inspiratory pressure 5-30 cm H2O Respiration rate 10-18 per minute PEEP 5-10 mmHg \*IBW: 50 + 0.91 (height in centimeters - 152.4) Peep, I:E ratio, and FiO2 will be administered at the anesthetic nurse's and the anesthesiologist's discretion.

Sponsors & Collaborators

  • University of Oslo

    collaborator OTHER

  • University Hospital, Akershus

    lead OTHER

Principal Investigators

  • Signe Søvik, Professor, MD, PhD · University Hospital, Akershus

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-24
Primary Completion
2026-06-30
Completion
2026-09-30

Countries

  • Norway

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06865027 on ClinicalTrials.gov